SEC Form 4 · accession 0001104659-17-032406

Aralez Pharmaceuticals Inc. · ARLZ

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

May 11, 2017

Accepted (ET)

May 12, 2017 · 9:50 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001660719

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Shares, without par value^F2	May 11, 2017	A	7,500	$0.00	A	15,000	D
Common Shares, without par value^F3	holding	—	—		—	343,216	I	By JALAA Equities, LP

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Director Stock Option (right to buy)^F4	$1.56	May 11, 2017	A	15,000	A	—	May 11, 2027	Common Shares, without par value	15,000	15,000	D

F1Restricted Stock Units, all of which vest on May 11, 2018, subject to the director's continued service on the Board as of such date. Vested shares will be delivered to the Reporting Person on the earlier of the date that the Reporting Person ceases to provide services to the Board and the date of a Change of Control, as defined in the Issuer's 2016 Amended and Restated Long-Term Incentive Plan, in either case provided that the Restricted Stock Units are vested on such date.
F2Includes 7,500 Common Shares and 7,500 Restricted Stock Units.
F3Securities are owned by JALAA Equities, LP, of which the Reporting Person is the general partner. By reason of the provisions of Rule 16a-1 under the Securities Exchange Act of 1934, as amended, the Reporting Person may be deemed to be the beneficial owner of the securities owned by JALAA Equities, LP.
F4The option vests in one installment on May 11, 2018, subject to the director's continued service on the Board as of such date.